Article
Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells.
Division of Hematology/Oncology, Mayo Clinic-Jacksonville, Mayo Medical School, Jacksonville, Jacksonville, FL, USA.
International Journal of Cancer (impact factor:
5.44).
04/2003;
104(1):19-27.
DOI:10.1002/ijc.10880
pp.19-27
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.
[show abstract] [hide abstract]
ABSTRACT: Anti-Human Epithelial Receptor Type 2 (HER2) antibodies have the ability to induce in vitro apoptosis of glioblastoma (GBM) cells. This study was designed to evaluate the variability of HER2 expression in GBM and its role as a possible prognosis factor. Data of 57 patients with GBM and 16 patients with grade III gliomas were retrospectively analyzed. The expression of HER2 was determined by immunohistochemistry and intensity was noted from 0+ to 3+. We compared the HER2 expression in de novo GBM and in GBM resulting from anaplastic transformation of low-grade glioma ("secondary GBM"). Statistical analysis was performed using univariate analysis and the Kaplan-Meier method. All GBM expressing highly HER2 (2+ and 3+) were de novo GBM. All secondary GBM expressed HER2 with low intensity (0+ and 1+). Survival time was significantly longer when HER2 expression was low (Log Rank test P = 0.04). The patterns of HER2 expression were similar between grade III gliomas and secondary GBM. To our best knowledge, our study showed for the first time a significant association between HER2 expression and the type of GBM, with subsequent influence on survival rate. GBM with low-HER2 expression are more likely to be secondary GBM, carrying a better prognosis than de novo GBM.Journal of Neuro-Oncology 01/2008; 85(3):281-7. · 3.21 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
constitutive phosphorylation
constitutively phosphorylated Erk
detectable stat3 DNA-binding complexes
downstream effectors Erk
EGF treatment
EGFR kinase inhibitor PD158780
EGFR protein
human glioblastomas
maintains EGFR gene amplification
malignant phenotype
minimal growth conditions
overexpress intact receptors
overexpressed EGFRs
Overexpressed epidermal growth receptor factor receptors
rare GBM cell line
receptors
related receptors HER2/neu
SKMG-3 cells
SKMG-3 EGFRs
unstimulated SKMG-3 cells